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Malignant transformation may be viewed as an imbalance between signals inducing cell growth and
signals leading to growth inhibition, differentiation, or senescence. A basic understanding of how these
counterbalancing forces interact to regulate normal cell growth is the prerequisite to comprehending the
mechanisms oftumorigenesis. Identification and characterization ofthe gene products implicated in these
regulatory pathways is the first step toward understanding the disease process. The studies outlined here
provide the potential basis for isolating and molecularly characterizing transformation effector and sup-
pressor genes, which must respectively function in the positive and negative regulation of normal cell
growth. The general strategy used involves the isolation andmolecularcharacterization ofnontransformed
variants (revertants) from populations of tumor cells. The selection of revertants is facilitated by the
ability to separate normal from transformed cells by fluorescence-activated sorting. The basis for this
separation is the differential retention ofthe fluorescent dye rhodamine 123 in the mitochondria ofnormal
versus transformed cells. Using this approach, we have isolated revertants from a mutagenized population
ofv-fos-transformed Rat-1 fibroblasts. Characterization of these clones indicated that they had sustained
causal mutations in transformation effector genes. The unmutated effector genes are being identified and
molecularly cloned by isolating retransformed clones from revertant cell lines that have been transfected
with DNA or cDNA from normal primary cells. The same selection protocol has also been used to isolate
revertants from tumor cell lines that have been transfected with DNA or cDNA from primary cells. The
putative tumor-suppressor genes present in these revertants are currently being analyzed.
Transformation Effector Genes
Dominant transforming genes or oncogenes were in-
itially identified as the oncogenic elements ofthe acute
transforming retroviruses. Within the context of a ret-
rovirus, these oncogenes appear to be both necessary
and sufficient for the initiation of tumorigenesis (1). It
was the pivotal studies of Stehelin et al. (2) that first
indicated that the retroviral oncogenes were not viral
in origin, but rather were derived from cellular proto-
oncogenes that had recombined with the viral genome
during the course of infection. These findings provided
concrete evidence for the notion that eukaryotic ge-
nomes harbored genes whose alteration and/or altered
expression could give rise to the transformed pheno-
type. The subsequent search for oncogenes in human
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and animal tumors has resulted in the identification and
molecular cloning of approximately 50 oncogenes and
putative oncogenes (3). A great deal ofinformation con-
cerning the structure of these oncogenes, the proteins
they encode, and the molecular mechanisms leading to
proto-oncogene activation has been rapidly amassed.
The functions of oncogenes and their corresponding
proto-oncogenes in normal and transformed cells are
also emerging. The different oncoproteins are localized
invarious compartments ofthecell (nucleus, cytoplasm,
cell membrane, or cytoskeleton) and have diverse func-
tional characteristics including GTP-binding activity,
tyrosine kinase activity, and function as growthfactors,
assoluble ormembrane-associatedreceptorsforgrowth
factors orhormones, and as second messengers coupled
to receptors (1,3-8).
Whereas much is known about the properties of the
different oncogenes, less is known about the cellular
components with which specific oncogenes interact and
the cellular processes through which these oncogenes
induce cell transformation. Theoretically, it should be
possible to characterize cellular genes required forZARBL ETAL.
transformation by isolation and molecular characteri-
zation of revertants (nontransformed variants) from
populations of cells transformed by specific oncogenes.
Somatic mutations that could give rise to the revertant
phenotype include those resulting in the inactivation of
the oncogene, those resulting in the activation of dom-
inant transformation suppressor genes, and those lead-
ing to the inactivation ofeffector genes involved in the
cellular processes required for transformation by a
given oncogene. Effector genes would include those
genes whose expression is altered by the oncogene,
genes that directly or indirectly affect the function of
the oncoprotein, and genes comprisingthe complex mo-
lecular pathways that produce the pleiotropic pheno-
type oftransformed cells.
A number of flat revertants have been isolated from
populations of cells transformed by a variety of onco-
genes. The majority of these, however, resulted from
mutations affectingthe expression ofafunctionaltrans-
forming protein (9-19). A few cell lines arising from
apparent mutations in cellular effector genes (20-24) or
suppressor genes (25) have been isolated from rodent
fibroblasts transformed by either v-ras, v-abl, v-mos,
SV-40 T-antigen, orby adenovirus infection (26). These
revertants were derived by treating mutagenized pop-
ulations of transformed cells with various cytotoxic
agents that are toxic to growing cells or cancer cells.
Cultures were exposed tothese agentsunderconditions
where cells that had reacquired a nontransformed phe-
notype were contact inhibited and hence were less sus-
ceptible to these cytotoxic agents. These conditions
therefore ledtothepreferentialelimination ofthetrans-
formed parental cells and after several cycles ofgrowth
followed by selective killing, permitted the isolation of
morphologic revertants. In addition to being both in-
efficient and time consuming, this type of selection is
based on differential growth parameters ofnormal ver-
sus transformed cells and hence may have precluded
the isolation ofcertain classes ofrevertants. Moreover,
the selection procedure itself may have induced epige-
neticchangesorchangesinthenumberofchromosomes.
Furthermore, if the cytotoxic agents used were them-
selves mutagenic, then their continuous presence dur-
ing the selection period may generate a revertant phe-
notype resulting from multiple mutational events.
While any ofthese mechanisms would result in the pro-
duction of a revertant phenotype, the nature of these
genetic orepigenetic changes may preclude theiranaly-
sis by gene transfer experiments. It was therefore de-
sirable to develop a rapid and efficient selection pro-
cedure that would permit the isolation of revertants
resulting from a single mutational event.
The selection protocol developed is based on the pro-
longed retention of a fluorescent molecule within the
mitochondria ofmany transformed cells relative to non-
transformed cells (27-32). While the prolonged dye re-
tention phenotype is neither essential nor sufficient for
celltransformation, inmanycellsitappears tobetightly
coupled to the mechanisms of transformation. Muta-
genized populations of transformed cells can therefore
be stained, destained overnight, and revertants se-
lected by fluorescence-activated cell sorting. This pro-
cedure allows for isolation of revertants with unprece-
dented speed and efficiency and without exposure ofthe
cells to additional selective pressures. It is therefore
very unlikely that the selection procedure itself will
contribute to induction ofthe revertant phenotype. Ge-
netic changes in the resulting revertants should there-
fore reflect the specificity of the mutagen used.
Despite the fact that the prolonged dye retention
phenotypeisnotabsolutelylinkedto celltransformation
(33), our results have already validated the usefulness
of this selection protocol in the isolation of revertant
celllines. Followingrandommutagenesis ofv-fos-trans-
formed fibroblasts, cells displaying a transient rhoda-
mine-retention phenotype were selected by fluores-
cence-activated cell sorting. Characterization of the
individual clones revealed that unlike the transformed
parental cells, the revertants isolated with this protocol
had a stable nontransformed morphology, were contact
inhibited, failed to grow in soft agar, and were not tu-
morigenic wheninjectedintosyngeneicFischer344 rats
or athymic nude mice. In addition, the revertant cells
retained a functional transforming FBJ-MuSV that
could be rescued by infection with a replication-com-
petent Moloney murine leukemia virus. Immunoprecip-
itation experiments indicated that the levels ofthe p55
v-fosproteinpresentintherevertantswere comparable
to the levels present in the transformed parental cells.
Thus, the revertant phenotype was not the result of
mutations affectingthe activity orthe expression ofthe
oncogene present in the transforming FBJ-MuSV pro-
virus. Therevertants expressed afunctionaltransform-
ing v-fos gene, but were resistant to its transforming
potential. More importantly, the revertants were also
resistant to transformation by a variety of other onco-
genes but could be transformed by the polyoma middle
T-antigen as well as the neu and trk oncogenes. Taken
together, theseresultsindicated thattherevertant cells
had sustained mutations in one or more cellular genes
that control transformation of Rat-1 fibroblasts by p55
v-fos and a variety of other oncogenes. These findings
were consistent with the notion that several oncogenes
may share commonbiochemicalpathwaysleadingto cell
transformation.
Strategy for Cloning v-fos
Oncogene-Specific Transformation
Effector Genes
Somatic cell fusion experiments were used to estab-
lish the dominant or recessive nature of the revertant
phenotype in each of the revertant clones. The results
of these experiments indicated that the revertant phe-
notype was recessive in hybrids formed between each
oftherevertants and v-fos-transformed cells, rulingout
the possibility that the revertant phenotype was in-
duced by the activity ofadominant transformation sup-
pressor gene. This interpretation was corroborated by
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experments in which the revertants were fused with
nontransformed Rat-i fibroblasts. The hybrid cell lines
derived from these fusions reacquired a transformed
phenotype, suggestingthattherevertantphenotype re-
sulted from the inactivation oftransformation effector
genesthatwerepresentinbothnormalandtransformed
fibroblasts. The dominance of the transformed pheno-
type in somatic cell hybrids indicated that it should be
possible to identify the causal effector genes using
DNA-mediated gene transfer experiments. The rever-
tant clones have thus been transfected with genomic
DNA or with cDNA libraries prepared in eukaryotic
expression vectors with mRNA isolated from normal
human and rodent fibroblasts.
Evidence from the analysis ofthese retransformants
indicates that at least two of the revertant clones can
beretransformedbyvectors thatconstitutively express
thec-junproto-oncogene orthev-junoncogene (J. Van
Amsterdam, R. C. Sullivan, and H. Zarbl, in prepa-
ration). We have further shown that retransformants,
generated by transfection ofrevertant clone EMS-1-19
with DNA from normal human cells, also harbor a c-
jun-related gene. Although all these results are con-
sistent with a causal mutation in the c-jun proto-onco-
gene, to date sequence analysis of about 80% of the
nucleotides composing each ofthe c-jun alleles present
in clone EMS-1-19 and Rat-1 cells have failed to detect
mutations that might lead to an altered c-jun protein.
Analternativeinterpretationofthedataobtainedisthat
the causal mutation in clone EMS-1-19 is actually in a
c-jun-related sequence, and that the overexpression of
c-jun or v-jun alleles is able to compensate for this
mutation. Similarly, itispossiblethatthecausaleffector
gene mutation is in a totally unrelated gene, and that
jun oncoproteins transform cells via afos-independent
mechanism. Additionalexperimentsarerequired todis-
tinguish between these possibilities.
The experimental results implicating c-jun as a pu-
tative v-fos transformation-specific effector gene led us
to an independent experimental approach. The hypoth-
esis thatc-junis afostransformation effectorgene pre-
dicts that c-jun is necessary forfos-induced cell trans-
formation. Hence, inhibition ofc-jun expression would
beexpectedtoinhibitv-fos-induced celltransformation.
We have therefore generated vectors which are able to
constitutively express anti-sense c-jun RNA. We have
obtained preliminary data suggesting that it is indeed
possible to suppress v-fos-induced cell transformation
by expressing anti-sense c-jun mRNA. Analyses ofthe
levels of c-jun mRNA and protein in these cells are
being performed to test the validity of these observa-
tions.
Tumor-Suppressor Genes
It is generally accepted that oncogene-induced cell
transformation represents a genetically dominant phe-
notype. However, studies performed over the last 20
yearshaveclearlydemonstrated thatthe cancerpheno-
type canalso berecessive, gvingrise to thehypothesis
that there are genes present in normal cells that func-
tion as negative regulators of cell growth. These sup-
pressor genes or anti-oncogenes differ from oncogenes
in that their function must be lost before a cell can
acquire a cancerous phenotype. Evidence for tumor
suppression was first provided by studies demonstrat-
ing that the tumorigenic phenotype is usually sup-
pressed in somatic cell hybrids between normal and
transformed cell lines (34,35), with retransformed seg-
regants arising only after loss of specific normal chro-
mosomes. Repression of the cancer phenotype is also
observed when malignant cells are introduced into cer-
tainembryonicenvironments(36-38). Evidenceforsup-
pressor genes is also derived from the analysis of the
autosomal dominant patterns of inheritance of certain
familial cancers. These analyses lead to the hypothesis
thatcarrierswereheterozygousforrecessivemutations
in suppressor genes. Cancers would then arise in indi-
vidual cells that become homozygous for loss of sup-
pressor gene function as a result of somatic mutations
(39).
Over the past few years, this model has been con-
firmed by the identification of deletions in a defined
region of chromosome 13 in human familial retinoblas-
tomabyusingcytogenetic observations and restriction-
fragment-length polymorphism (RFLP) analyses with
informative allele specific probes (40,41). Subsequent
studies by several groups culminated in the molecular
cloning of the retinoblastoma (Rb) suppressor gene
(42,43) and in the demonstration that introduction of
the cloned gene into retinoblastoma cell lines resulted
in suppression oftheir tumorigenic phenotype (44). Al-
though the loss of the Rb gene was initially identified
with heritable forms of retinoblastoma and osteosar-
coma, it is now clear that Rb gene mutation is also
involved in sporadic retinoblastoma and in a variety of
nonhereditary forms ofcancer including small cell car-
cinoma ofthe lung (45,46), bladder carcinoma (47), and
breast cancer (48,49).
Usingapproaches similartothoseused toidentifythe
Rb gene, deletions ofspecific chromosomal regions are
being identified in an increasing number of human tu-
mors [for recent reviews see Green (50), and Cavanee
et al. (51)]. A great deal ofeffort is thus being directed
toward the molecular cloning of the putative tumor-
suppressor genes associated with the specific chromo-
somal regions for which loss of heterozygosity is fre-
quentlyseen in specific tumortypes. The first approach
being used to clone putative suppressor genes is the
same as that which proved successful in cloning the Rb
gene and involves chromosome walking from RFLP
markers that flank the region containing the putative
suppressor gene. This methodology has recently been
applied to the analysis of alleles located on the short
arm of chromosome 17 and on the long arm of chro-
mosome 18, which are frequently deleted in human co-
lorectal cancer (52-54). Results of this analysis indi-
catedthatthedeletedregionsonchromosome 17include
the p53 suppressor gene. Sequence analysis of the p53
alleles remaining in most colorectal cancer cells indi-
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cated that they had sustained inactivating point muta-
tions (53). Inactivating mutations in remaining p53 al-
leles were also seen in most brain, breast, and lung
tumors that showed allelic deletions on chromosome
17p, and in some tumors without 17p allelic deletions
(55). All ofthese results are consistent with the notion
that inactivation of the p53 suppressor gene may be
associated with several unrelated tumor types. Despite
the success of the "brute force" approach described
above, its application is limited to the analysis ofthose
putative suppressor genes for which closely linked
(within walking or jumping distance) RFLP markers
are available.
An additional approach being employed to identify
tumor-suppressor genes involves refinements ofthe so-
matic cell fusion technology, which first provided evi-
dence for their existence. In this technique, normal cell
lines in which single chromosomes are tagged with se-
lectable marker genes are generated. Microcell fusion
is then used to transfer single chromosomes into tumor
cells, and cells that harbor the tagged chromosome are
assayed for the presence of suppressor genes (51,56).
The putative suppressor genes expressed from these
chromosomes or chromosomal fragments could then be
identified among the clones isolated by generating
cDNAsubtraction libraries betweentheparental tumor
cell line and the revertant recipient cell (51,57) using
functional suppression assays (see below). Alterna-
tively, the suppressor gene residing in the exogenous
chromosomes could be inactivated in the suppressed
recipient cell by retroviral insertional mutagenesis and
the viral sequences used to clone the inactivated sup-
pressor gene sequences in the retransformed clones
(58,59).
The methodologies outlined above are contingent on
the abilityofthe suppressorgene torepress aselectable
cancer phenotype in the recipient cell. However, recent
results from several laboratories have provided evi-
dence that loss ofspecific chromosomal regions contain-
ing putative suppressor genes may also play a role in
malignant progression of a number of common human
tumors (45,51-54,60,61). It can thus be speculated that
it is the accumulated loss of heterozygosity (LOH) at
several alleles that is responsible for induction of ma-
lignant cancers. The possibility therefore exists that
individual suppressor genes associated with LOH for
individual chromosomal regions may not be capable of
inducing phenotypic reversion of tumor cells. Even
though loss of each of these genes may contribute to
tumorprogression, it may not be detectable in suppres-
sion assays (cell fusion, microcell fusion, DNA trans-
fection) dependent on a reduction in tumorigenicity of
recipient cells. The ability to identify and clone such
suppressor genes represents an even greater problem
in those tumor cells where loss of gene function is not
associated with a cytogenetically detectable LOH or by
RFLP analysis. Such genes could only be detected by
assays in which tumor cells at a specific stage of pro-
gression are shown to revert to a less aggressive his-
topathologic stage afterintroduction ofafunctionalsup-
pressor gene.
Reznikoff and her co-workers (62-64) have recently
developed an experimental system that is uniquely
suited to the identification of suppressor genes whose
loss of function contributes to tumor induction and/or
progression. These investigators produced a partially
transformed, nonvirus-producing cell line by infecting
primary human uroepithelial cells (HUC) with Simian
virus 40 (SV40). This cell line (SV-HUC-1) was clonal,
showed anchorage-independent growth in vitro, but
failed to produce tumors in nude mice, even after more
than 80 passages in vitro. While this cell line was found
to be cytogenetically unstable, the continuous karyo-
typic rearrangements did not lead to tumorigenic con-
version. The marker chromosomes formed were shown
to be the result ofbalanced translocations, resulting in
the production of a pseudodiploid cell line. The SV-
HUC-1 cell line was then exposed to carcinogens in
vitro, and tumorigenic progression monitored by injec-
tion of treated cells into athymic nude mice. The most
important observation from these studies is that the
resulting tumors collectively recapitulate the full spec-
trum of histopathology seen in human bladder cell car-
cinoma. Moreover, all cell lines isolated from tumors
showed stable marker chromosomes and LOH for sev-
eral chromosomal regions, with more malignant tumor
types showing a greater accumulation of chromosomal
changes.
The major advantage ofthis system is that all ofthe
tumors generated are derived from the SV-HUC-1 cell
line and hence should differ from one another by a lim-
ited number of genetic alterations. Suppressor genes
whose inactivations are involved intumorinduction and
progression could thus be identified using subtractive
cDNA libraries prepared from tumors representing se-
quential histopathologic stages or by retroviral inser-
tional mutagenesis as described above. Such studies
would be muchmore difficultusingtumorsrepresenting
different histopathologic stages of progression that
were not derived from the same individual.
An additional in vitro assay is currently being used
to identify putative suppressor genes, particularly in
those cases where the presumed loss of a suppressor
gene is not associated with any particular cytogeneti-
callyvisiblechange orwithinformative RFLPmarkers.
This approach is contingent onthe ability to detect sup-
pressor gene activity in afunctional assay. Thus, tumor
cells are transfected with genomic DNA from normal
cells (65) or with cDNA libraries from normal cells,
prepared in eukaryotic expression vectors (66,67). Re-
vertant cell lines, which have presumably acquired a
functional suppressor gene, are then isolated and the
putative suppressor genes characterized. Inherent in
such an approach are two major drawbacks. The first
potential problem arises ifthe gene that is able to sup-
press the transformed phenotype also suppresses cell
growth. The inability to expand the resulting revertant
cells would prohibit their characterization and analysis
ofthe causal gene. It is therefore likely that functional
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assays would detect only a subset ofsuppressor genes.
In this regard the recent result demonstrating that the
transformed phenotype ofretinoblastoma cell lines can
be suppressed by infection with retroviral constructs
expressing theRb gene (44) are reassuring and provide
support for the feasibility of using such a functional
approach. The secondpotential problemassociated with
using these gene transfer experiments is that the genes
able to suppress cell transformation in the assay do so
via a nonphysiological mechanism. It is probable that
the constitutive overexpression of a gene could simply
titrate away cellular factors required for cell transfor-
mation or simply gum up the biochemical machinery of
the cell in a nonspecific way that will also inhibit cell
transformation. Such transformation-reverting genes,
while providing important information about the mo-
lecularbiochemistry ofcell transformation, could not be
classified as true tumorsuppressor genes. Nonetheless,
it is anticipated that among the genes isolated by this
approach will be some genes that are indeed tumor-
suppressor genes. Indeed, the retinoblastoma gene
could have been identified using a suppression assay
(44).
Strategy for Cloning Human and
Rodent Suppressor Genes
Using the functional approach described above, a
number ofgenes able to suppress the transformation of
fibroblasts by the K-ras oncogene have been recently
cloned (65-67). A similar approach is also being used in
our laboratory to isolate genes able to suppress v-fos-
induced cell transformation and to isolate genes able to
suppress the transformed phenotype of various human
carcinoma cell lines.
Encouraged by the initial success in the isolation of
revertants harboring effector gene mutations, we have
applied the same techniques toward the isolation ofre-
vertants harboring transformation-suppressor genes.
The approach taken is based on the assumption that
transformation-suppressor genes normally function as
regulators ofcellgrowth and are thus expressed in non-
transformed cells. We have, therefore, prepared cDNA
from normal fibroblasts and cloned these cDNAs into
eukaryoticexpression vectors. DNAisolatedfromthese
cDNA libraries is subsequently cotransfected into
transformed cell lines along with the pSV2 neo plasmid
and transfectants selected with G418. Amongthe trans-
fectants shouldbecellsthatareexpressingasuppressor
gene mRNA from atransfected cDNA expression plas-
mid (44,67). It should bepossible toisolatetheresulting
revertant clones by fluorescence-activated cell sorting,
given that the revertant phenotype includes loss ofpro-
longed rhodamine retention. In a preliminary set ofex-
periments (C. J. Kho and H. Zarbl, in preparation), we
havebeenabletoisolateseveralmorphologicrevertants
from v-fos-transformed fibroblasts transfected with
DNA from a human foreskin fibroblast cDNA expres-
sionlibrary. Atleast one suchrevertanthasbeenshown
to contain a transfected eDNA expression plasmid,
which is currently being characterized.
The prolonged rhodamine 123 retention phenotype is
associated with most transformed cell lines ofepithelial
origin (29). We are applying our selection procedure to
the isolation ofsuppressor genes that are able to revert
the phenotype oftumor cell lines derived from the most
common forms ofhuman carcinomas. Cell lines derived
from human carcinomas are therefore beingtransfected
with cDNA expression libraries prepared with mRNA
from either primary fibroblasts, or from cell lines de-
rivedfromthe sametissue asthecorrespondingtumors.
The transfectants are then sorted on the basis oftheir
dye retention phenotype in order to isolate revertants.
Results ofpreliminary experiments are expected in the
near future.
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